By Michael Dabaie 



  AstraZeneca and Merck & Co. said Lynparza demonstrated a long-term progression-free survival benefit versus placebo. 


  The companies said Lynparza demonstrated a long-term progression-free survival benefit versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who had a complete or partial response following platinum-based chemotherapy. 


  Five-year follow-up data from the Phase III SOLO-1 trial showed Lynparza reduced the risk of disease progression or death by 67% and improved progression-free survival to a median of 56.0 months versus 13.8 months for placebo. 


  At five years, 48.3% of patients treated with Lynparza remained free from disease progression versus 20.5% on placebo. 


  The median duration of treatment with Lynparza was 24.6 months, versus 13.9 months with placebo, the companies said. 


  Write to Michael Dabaie at michael.dabaie@wsj.com